21/543 Efficacy trials in regenerative medicine
Closing date: 1:00 pm, 7 December 2021 (two stage – Stage 1 to Stage 2)
The EME Programme invites applications to evaluate the efficacy of interventions in the field of regenerative medicine.
This call includes all types of novel technology for which clinical proof of concept, i.e. safety and a signal of efficacy in patients, can be demonstrated. Areas of particular interest include, but are not limited to:
- Gene therapies for rare disorders
- Evaluation of regenerative technologies, including novel smart materials, which builds on previous publicly and charity-funded research
The EME Programme is also keen to receive proposals developed in collaboration with industry partners. Applicants from industry who wish to identify academic or clinical partners may wish to contact the NIHR Office for Clinical Research Infrastructure (NOCRI) at: email@example.com.
Applicants are also encouraged to engage with the MHRA Regulatory Advice Service for Regenerative Medicines for regulatory information, advice and guidance where necessary.